Last updated: 2026-09-05 02:56:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Amgen Inc. (AMGN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $437.20, with a market capitalization of $239.41B and a P/E ratio of 27.46. Over the past 52 weeks, its price has ranged from $269.77 to $447.03. This page covers its latest market performance, valuation, price trends and company information.
$239.41B | |
$437.03 | |
$447.03 | |
$27.00 | |
$444.12 | |
982.28K | |
-- | |
27.46 | |
$447.03 | |
$269.77 | |
2.20% | |
-- |
Amgen Inc. (AMGN) last closed at $444.12 as of 2026-09-05 00:00:00, unchanged from the previous close of $444.12.
During the latest regular trading session, AMGN traded between $27.00 and $447.03, with a volume of 982.28K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Amgen Inc. (AMGN) moved from $428.59 to $437.20, representing a gain of 2.01% ($8.61).
The stock traded between $436.19 and $444.42 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 2.00 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 94.5%
AMGN is currently trading at $437.20, placing it 94.5% of the way from its 52-week low of $269.77 to its 52-week high of $447.03. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 31500 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Amgen Inc. (AMGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.